Home Companies Catalysts Deep Dives
torvutatug samrotecan torvutatug samrotecan PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$2000M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: EGFR-directed (samrotecan payload)
Expert: Antibody-drug conjugate targeting EGFR with topoisomerase I inhibitor payload.
Everyday: An antibody-drug combination targeting EGFR protein to deliver chemotherapy directly to cancer cells.
Targets: ["EGFR"]
Programs (1)
IndicationStageKey StudyRegional Status
Solid (EGFR+)PHASE1—[]
Notes
FRα ADC for ovarian cancer.
Data from Supabase · Updated 2026-03-24